EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies

Mohammed Aboukaoud iD, Yocheved Morhi, Ester Osher

Annals of Pharmacotherapy · 2025-10 · 59 (10) · 891-903

DOI: 10.1177/10600280241312432 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 30.01.2025. Verfasst von Mohammed Aboukaoud und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Internal Medicine, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Urinary Tract Infections, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

There is limited knowledge about severe urinary tract infections associated with SGLT2i, despite this being the basis for the Food and Drug Administration (FDA) warning. We aim to provide real-world evidence to clarify this relationship further. Data source: A literature review was performed in PubMed and Embase for cohort studies published up to August 2024 using PICO-consistent terms. Study selection and data extraction: Cohort studies in English involving new users of SGLT2i that compare SGLT2i with glucagon-like receptor agonists (GLP-1RA), DPP4i, and other glucose-lowering medications and report severe urinary tract infection (UTI). Data synthesis: The random-effect model determined the odds ratio (OR) and 95% confidence interval (CI) for severe UTI. Subgroup analysis and meta-regression were used to identify sources of heterogeneity. In 11 cohort studies involving 679 617 individuals with type 2 diabetes mellitus and a median age of 64 (interquartile range [IQR] = 56-72) and 42% (IQR = 39%-51%) females, it was found that the use of SGLT2i was associated with a reduced risk of severe UTI compared with both composite glucose-lowering medications (OR = 0.73, 95% CI = 0.60-0.88) and DPP4i (OR = 0.48, 95% CI = 0.43-0.54). There was no significant difference in the risk compared with GLP-1RA (OR = 0.94, 95% CI = 0.78-1.14). Relevance to patient care and clinical practice: The lack of increased risk for severe UTI reassures physicians when assessing benefit-risk to continue SGLT2i after a severe UTI. This may enhance patient adherence and improve diabetes management. Furthermore, our findings show no significant risk increase in chronic kidney disease (CKD) patients who would benefit significantly from SGLT2i.

Conclusion

SGLT2i does not appear to pose a greater risk of severe UTI than other oral glucose-lowering medications. This contributes to the existing literature on UTI, accounting for the event’s severity. However, more data are needed to assess the potential association between SGLT2i and life-threatening UTI events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsUrinary Tract InfectionsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansCohort StudiesSeverity of Illness IndexFemale

Stichwörter der Autor:innen

glucagon-like peptide-1 receptor agonistsglucose-lowering medicationspyelonephritissodium-glucose co-transporter 2urinary tract infectionsurosepsis

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Internal Medicine, Rambam Health Care Campus, Haifa, Israel.
  • Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
  • Institute of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

ORCID-Profile: Mohammed Aboukaoud

Zitieren

APA

Aboukaoud, M., Morhi, Y., & Osher, E. (2025). Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies. Annals of Pharmacotherapy, 59(10), 891-903. https://doi.org/10.1177/10600280241312432

Vancouver

Aboukaoud M, Morhi Y, Osher E. Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies. Annals of Pharmacotherapy. 2025;59(10):891-903. doi:10.1177/10600280241312432

BibTeX
@article{Aboukaoud2025,
  author = {Aboukaoud, Mohammed and Morhi, Yocheved and Osher, Ester},
  title = {Sodium-Glucose Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  volume = {59},
  number = {10},
  pages = {891--903},
  doi = {10.1177/10600280241312432}
}
Kostenlos starten →